Illumina pushed back against Carl Icahn’s proxy fight over the Grail deal, saying it’s committed to maximizing shareholder value as it works with regulators.
You are here: Home / Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal